おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
AmpliMed Corporation
About
AmpliMed Corporation offers small molecule drugs for the treatment of cancer in the pancreas, ovaries and lungs.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $5M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 1989
- Number Of Employee
- 1 - 10
- Operating Status
- Active
AmpliMed Corporation focuses on the development of small-molecule oncology drugs. Its products include Amplimexon, a small molecule that causes cancer cells to stop dividing and ultimately to die; Amplizone that has demonstrated efficacy in the treatment of solid tumors in animal tumor models; and benzimidazole Series: benzimidazole analog small molecules that expressed tubulin binding activity in yeast and mammalian cells. The company’s products are used to treat pancreatic cancer, lung cancer, malignant melanoma, ovarian cancer, and multiple myeloma. AmpliMed Corporation was founded in 1989 and is based in Tucson, Arizona.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 14, 2008 | Series C | $5M | 1 | — | — | Detail |
| Jun 16, 2005 | Series B | $5M | 1 |
|
— | Detail |
| Sep 16, 2003 | Series A | $5M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
